Hirakawa H, Futagami M, Yokoyama Y, et al. Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary[J]. Gan To Kagaku Ryoho, 2011, 38(5): 857-860.
[2]
Taylor J, Amanze A, Di Federico E, et al. Irinotecan use during pregnancy[J]. Obstet Gynecol, 2009, 114(2): 451-452.
[3]
Wang L Y. AntineoplasticI irinotecan research progress [J]. Foreign Med Sci (SecPharm), 2004, 31 (1): 71.
[4]
Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer[J]. Gynecol Oncol, 2006, 100(2): 412-416.
[5]
Aoki Y, Kurata H., Watanabe M, et al. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer[J]. Am J Clin Oncol, 2004, 27(5): 461-464.
[6]
Hong Mh, Pei Yy. Hydroxycamptothecin and for mulations [J]. Chin J ClinPharm, 2008, 17(4): 255-258.
Kavanagh J, Sill MW, Ramirez PT, et al. PhaseⅡ multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study[J]. Int J Gynecol Cancer, 2008, 18(3): 460-464.
[12]
Pecorelli S, Ray-Coquard I, Tredan O, et al. PhaseⅡ of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes[J]. Ann Oncol, 2010, 21(4): 759-765.
[ 3 ] Wall ME, Wani MC, Cooke CE, et al. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from camptotheca acuminate[J]. J Am Chem Soc, 1966, 88(16): 3888-3890.
[16]
[ 4 ] Legarza K, Yang L-X. Novel camptothecin derivatives[J]. J In Vivo, 2005, 19(1): 283-293.
[17]
[ 5 ] Eng W-K, Faucette L, Johnson RK, et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin[J]. Mol Pharmacol, 1988, 34(6): 755-760.
[18]
[ 6 ] Tse YC, Kirkegaard K, Wang JC. Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA[J]. J Biol Chem, 1980, 255(12): 5560-5565.
[19]
[ 7 ] Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: evidence for cell cycle-independent toxicity[J]. J Cell Biol, 1996, 134(3): 757-70.
[20]
[ 8 ] Wu J, Yin M-B, Hapke G, et al. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin[J]. Mol Pharmocol, 2002, 61(4): 742-748.
[21]
[ 9 ] Collins I, Weber A, Levens D, et al. Transcriptional consequences of topoisomerase inhibition[J]. Mol Cell Biol, 2001, 21(24): 8437-8451.
[22]
Mosesso P, Pichierri P, Franchiitto A, et al. Evidence that camptothecin-induced aberrations in the G(2) phase of cell cycle of Chinese hamster ovary (CHO) cell lines is associated with transcription[J]. Mutat Res 2000, 452(2): 189-195.
[23]
Hayward RL, Macpherson JS, Cummings J, et al. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity[J]. J Clin Cancer Res , 2003, 9(7): 2856-2865.
[24]
Ullmannova V, Haskovec C. Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2[J]. Neoplasma , 2004, 51(3): 175-180.
[25]
Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events[J]. J Biol Chem, 2000, 275(13): 9501-9509.
[26]
Carson JP, Zhang N, Frampton GM, et al. Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin[J]. Cancer Res , 2004, 64(6): 2096-2104.
[27]
Flatten K, Dai NT, Vroman BT, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons[J]. J Biol Chem, 2005, 280(14): 14349-14355.
[28]
Wang H, Wang X, Shou X-Y, Ku, et al. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment[J]. Cancer Res, 2002, 62(9): 2483-2487.
[29]
Furuta T, Takemura H, Liao Z-Y, et al. Phosphorylation of histone H2AX and activation of Mre11,Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNAtopoisomerase I cleavage complexes[J]. J Biol Chem, 2003, 278(22): 20303-20312.
[30]
Adachi N, So S, Koyama H. Loss of nonhomologous end joining confers comptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage[J]. J Biol Chem, 2004, 279(36): 37343-37348.
[31]
Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin[J]. Cancer Res, 2003, 63(24): 8791-8812.
[32]
Jiang Q, Wang Hx. Research and Application of Camptothecins [J] . Prog Pharm Sci, 2007, 31(9): 408- 412.
[33]
Rowinsky EK, Grochow LB, Bendricks CB, et al. Phase I and pharmacologic study of topotacan: a novel topoisomerase I inhibitor[J]. J Clin Oncol, 1992, 10(4): 647 -656.
[34]
Kudelka Ap, Tres ukos ol D, Edwards Cl, et al. A Phase Ⅱ study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma[J]. J Clin Oncol, 1996, 14(5): 1552 -1557.
[35]
Gore M, Carmichael J, Gordon A, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer[J]. J Clin Oncol, 1997, 15(6): 2183- 2193.
[36]
Sehouli J, Stengel D,Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phaseⅢ study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group[J]. J Clin Oncol, 2008, 26(19): 3176-3182.
[37]
Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan paclitaxel noncross-resistance in ovarian cancer [J]. J Clin On col , 2001, 19(7): 1893-1900.
[38]
Coleman R L. Emerging role of topotecan in front line treatment of carcinoma of the ovary [J]. The On cologist, 2002, 7 ( S5) : 46-55.
[39]
Vecchione F, Fruscio R, Dell’Anna T, et al. A phaseⅡ clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2007, 17(2): 367-372.
[40]
Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer [J] . The Oncologist , 2002, 7(S5) : 29- 35.
[41]
Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy[J]. Oncology, 2007, 73(3-4): 177-184.
[42]
M？bus V, Kieback DG, Kaubitzsch SK. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis[J]. Anticancer Res, 2007, 27(3B): 1581-1587.
[43]
Calcagno M, Bellati F, Palaia I, et al. Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients[J]. Int J Gynecol Cancer, 2009, 19(3): 455-459.
[44]
Comander AH, Cannistra SA. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy[J]. Int J Gynecol Cancer, 2008, 18(1):51-58.
[45]
Muntz HG, Malpass TW, McGonigle KF, et al. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma[J]. Cancer, 2008,113(3): 490-496.
[46]
Sugiyama T, Yakushiji M, Ochiai K, et al. Japanese ovarian trials: focus on irinotecan[J]. Oncology (Williston Park), 2003, 17(Suppl 5): 29-33.
[47]
Takano M, Sugiyama T, Yaegashi N, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis[J]. Int J Clin Oncol, 2007, 12(4): 256-260.
[48]
Lee HP, Seo SS, Ryu SY, et al, PhaseⅡ evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or resistant ovarian cancer[J]. Gynecol Oncol, 2008, 109(3): 359-363.
[49]
Nam EJ, Kim JW, Kim JH, et al. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer[J]. Am J Clin Oncol, 2010, 33(3): 233-237.
[50]
Hee-Jung Ban, In-Jae oh, Kyu-Sik Kim, et al. Clinical efficacy of belotecan(CKD-602), newly developed camptothecin analog, in the 2nd line treatment of relapsed small cell lung cancer[J]. Tuberc Respir Dis, 2009, 66(2): 93-97.
[51]
Kim HS, Park NH, Kang S, et al. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience[J]. J Obstet Gynaecol Res, 2010, 36(1): 86-93.
[52]
Global Data. Karenitecin (Ovarian Cancer)- Analysis and Forecasts to 2020[DB/OL](2011-10-20)[2012-3-31]. http://www.pharmaceutical-market-research.com/publications/therapeutic/karenitecin_ovarian_cancer_analysis_forecast_2020.html.
[53]
Takakura S, Saito M, Ueda K., et al. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma[J]. Int Surg, 2007, 92(4): 202-208.
[54]
Nishino K, Aoki Y, Amikura T, et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma[J]. Gynecol Oncol, 2005, 97(3): 893-897.
